We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...
STAMFORD, Conn., May 16, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European ...
Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...
– Additional updates across Company’s commercial portfolio and investigational pipeline to be provided during J.P. Morgan Healthcare conference presentation today at 11:15 a.m. PT – STAMFORD, Conn., ...
SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo, for the treatment of adult patients with desmoid tumors. The approval is based on positive results from ...
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor ...
Stocktwits on MSN
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets
Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation ...
STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...
DURHAM, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies ...
NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...
Investing.com -- Shares of SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) climbed 2.7%, building on a previous gain of 2%, following the FDA approval of their drug, GOMEKLI, for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback